Compare GSK plc (GSK) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Otis Worldwide Corp — how do they compare? GSK plc trades at $52.6 (market cap $101.34B), while Otis Worldwide Corp trades at $74.58 (market cap $27.70B). The key difference: GSK plc is far larger — about 3.7× Otis Worldwide Corp's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | OTIS | |
|---|---|---|
Market Cap | $101.34B | $27.70B |
Sector | Health | Industrials |
52-Week High | $61.18 | $101.07 |
52-Week Low | $36.20 | $69.34 |
Enterprise Value | $121.95B | $35.09B |
Dividend Yield | 3.49% | 2.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Otis Worldwide (OTIS) trades at $74.47, up 2.63% on the day, with a bearish technical signal and mixed earnings performance. The stock shows stable revenue near $14.4B but recent EPS misses in Q1 2026. Valuation metrics include a P/E of 19.2 and P/S of 1.93, while cash flow trends indicate net outflows. Recent news highlights modernization projects and a 5% dividend increase to $0.44 per share.
Outlook is cautious with analyst consensus at Buy (38%) and a $91 price target, but risks include declining net income margin to 9.59% and high debt-to-asset ratio of 75.54%. Opportunities lie in service growth and strategic deployments, though China headwinds and margin pressures persist. Investors should weigh solid fundamentals against near-term earnings volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
